Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + dexamethasone + belantamab mafodotin
- Development stage
- Unknown
- Lead developer
- Karyopharm Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral (selinexor), Oral (dexamethasone), Intravenous (belantamab Mafodotin)
01
Overview
rejuvenates tumor suppressor proteins and induces apoptosis. - *Dexamethasone* is a synthetic glucocorticoid corticosteroid, used primarily for its anti-inflammatory and immunosuppressive effects, and as a backbone in myeloma regimens. - *Belantamab mafodotin* is a first-in-class antibody-drug conjugate that targets B-cell maturation antigen (BCMA) on myeloma cells. The afucosylated anti-BCMA humanized IgG1 antibody is conjugated to the cytotoxic payload monomethyl auristatin F (MMAF); upon binding and internalization, MMAF disrupts microtubule networks, induces cell cycle arrest at G2/M, and causes apoptosis. Belantamab mafodotin further promotes immunogenic cell death through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis[2][4][8]. This combination is being studied as a potential regimen for patients with RRMM, particularly those who have failed multiple prior lines of therapy[1][7].
- Other names
- selinexor + dexamethasone + belantamab mafodotin
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))BCMA (B-cell maturation antigen)XPO1 (Exportin-1)
Beyond the preview
Go deeper on selinexor + dexamethasone + belantamab mafodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + dexamethasone + belantamab mafodotin.